PEA-15 磷酸化状态与卵巢上皮性癌预后的相关分析

doi:10.12092/j.issn.1009-2501.2019.05.007

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (5): 523-528.doi: 10.12092/j.issn.1009-2501.2019.05.007

PEA-15 磷酸化状态与卵巢上皮性癌预后的相关分析

方川川¹，倪观太² ，金兰², 刘记², 刘晓庆¹，乔春¹, 罗永红²

¹皖南医学院，芜湖 241001,安徽；²皖南医学院第一附属医院弋矶山医院妇产科，芜湖 241001,安徽

收稿日期:2018-11-21 修回日期:2019-01-21 出版日期:2019-05-26 发布日期:2019-05-28
通讯作者: 罗永红，女，硕士研究生，主任医师，副教授，研究方向：妇科肿瘤。 Tel：13635537928 E-mail：lyh690906@126.com
作者简介:方川川，女，在读硕士研究生，研究方向：妇科肿瘤。 Tel：18355304030 E-mail：2539514075@qq.com
基金资助:
安徽省高等学校自然科学研究项目（KJ2017A265）

Correlation between phosphorylation of PEA-15-Ser104 site and prognosis of epithelial ovarian cancer

FANG Chuanchuan¹, NI Guantai², JIN Lan², LIU Ji², LIU Xiaoqing¹, QIAO Chun¹, LUO Yonghong²

¹Wannan Medical College, ² Department of Obstetrics and Gynecology，the First Affiliated Hospital of Wannan Medical College，Wuhu 241001，Anhui,China

Received:2018-11-21 Revised:2019-01-21 Online:2019-05-26 Published:2019-05-28

摘要/Abstract

摘要：

目的:检测卵巢上皮性癌组织中pPEA-15-Ser104表达水平，探讨其临床意义及与卵巢上皮性癌预后的相关性。方法:选取2009年1月至2013年6月收住皖南医学院第一附属医院弋矶山医院妇产科手术治疗并经病理证实的95例原发卵巢上皮性癌，所有患者术前均未行化疗。免疫组化方法检测95例原发卵巢上皮性癌pPEA-15-Ser104的表达水平，卡方检验分析pPEA-15-Ser104表达水平在不同临床特征卵巢癌患者中差异并随访患者生存情况，采用Kaplan-Meier（K-M）方法分析不同临床特征卵巢上皮癌患者生存率差异，应用多因素Cox比例风险回归模型分析卵巢上皮性癌患者预后影响因素。结果:pPEA-15-Ser104的表达在不同组织学分级、手术病理分期、分型以及有无远处转移的卵巢上皮性癌组织中的表达比较差异均具有统计学意义（P<0.05）；而在年龄、肿瘤位置、肿瘤最大径、有无淋巴结转移比较中差异无统计学意义。K-M生存分析和Cox回归分析显示，pPEA-15-Ser104高表达的卵巢癌患者预后不良，生存时间短，pPEA-15-Ser104可作为卵巢癌不良预后的独立危险因素。结论:磷酸化状态的PEA-15在卵巢上皮性癌的发展过程中发挥重要作用，高表达者预后不良，可能成为预测卵巢癌患者预后的新靶标，有望为卵巢癌患者的治疗提供重要靶点。

关键词: 卵巢上皮性癌, pPEA-15-Ser104, 预后, 免疫组化

Abstract:

AIM: To detect the expression level of pPEA-15-Ser104 in epithelial ovarian carcinoma and to explore its clinical significance, and the correlation with the prognosis of epithelial ovarian carcinoma. METHODS: From January 2009 to June 2013, 95 cases of primary ovarian epithelial carcinoma who were admitted to the First Affiliated Hospital of Wannan Medical College Yijishan Hospital for gynecology and obstetrics surgery and pathologically confirmed were selected. All the patients were not treated with chemotherapy before surgery. The expression levels of pPEA-15-Ser104 in 95 cases of primary ovarian epithelial carcinoma were detected by immunohistochemical method.Chi-square test was used to analyze the difference of pPEA-15-Ser104 expression in patients with ovarian cancer with different clinical characteristics. Survival status of patients with ovarian epithelial carcinoma was closely followed up after surgery . Kaplan-Meier (K-M) method was used to analyze the difference of survival rate in patients with ovarian epithelial carcinoma with different clinical characteristics. Multivariate Cox proportional risk regression model was used to analyze prognostic factors in patients with epithelial ovarian carcinoma.RESULTS:There were significant differences in the expression levels of pPEA-15-Ser104 in different histological grades, surgical and pathological stages, types and distant metastasis of ovarian epithelial carcinoma.There was no significant difference in age, tumor location, tumor maximum diameter and lymph node metastasis.K-M survival analysis and Cox regression analysis showed that the prognosis of ovarian cancer patients with high expression of pPEA-15-Ser104 was poor and the survival time was short, which could be used as an independent risk factor for poor prognosis of ovarian cancer (P<0.05).CONCLUSION: Phosphorylated PEA-15 plays an important role in the development of ovarian epithelial carcinoma.The prognosis of the patients with high expression is poor. It may become a new target to predict the prognosis of ovarian cancer patients, and it is expected to provide an important target for the treatment of ovarian cancer patients.

Key words: epithelial ovarian cancer, pPEA-15-Ser104, prognosis, immunohistochemistry

中图分类号:

R965.2
R711

方川川，倪观太，金兰, 刘记, 刘晓庆，乔春, 罗永红. PEA-15 磷酸化状态与卵巢上皮性癌预后的相关分析[J]. 中国临床药理学与治疗学, 2019, 24(5): 523-528.

FANG Chuanchuan, NI Guantai, JIN Lan, LIU Ji, LIU Xiaoqing, QIAO Chun, LUO Yonghong. Correlation between phosphorylation of PEA-15-Ser104 site and prognosis of epithelial ovarian cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 523-528.

参考文献

［1］Mcguire V, Jesser CA, Whittemore AS.Survival among U S women with invasive epithelial ovarian cancer［J］. Gynecol Oncol, 2002, 84(3):399-403.
［2］Vigliotta G, Miele C, Santopietro S, et al. Overexpression of the ped/pea-15 Gene causes diabetes by impairing glucose-stimulated insulin secretion in addition to insulin action［J］. Mol Cell Biol, 2004, 24(11):5005-5015.
［3］Geng F, Wu JL, Lu GF, et al.MicroRNA-132 targets PEA-15 and suppresses the progression of astrocytoma in vitro［J］. J Neurooncol, 2016, 129(2):211-220.
［4］吴益峰, 朱柯磊, 陈磊,等.肝细胞性肝癌中磷酸化PED/PEA-15和P-p27T187的表达及临床意义［J］. 现代实用医学, 2016, 28(9):1134-1138.
［5］刘记, 金兰, 罗永红. PED/PEA-15及其磷酸化状态在卵巢上皮肿瘤中的表达及意义［J］.现代妇产科进展, 2016, 25(7):19-22.
［6］陈春林.卵巢肿瘤、输卵管肿瘤及原发性腹膜癌［M］//谢幸，孔北华，段涛，主编. 妇产科学. 9版.北京.人民卫生出版社，2018:313-323.
［7］Harris HR, Babic A, Webb PM, et al. Polycystic ovary syndrome, oligomenorrhea, and risk of ovarian cancer histotypes: Evidence from the Ovarian Cancer Association Consortium［J］. Cancer Epidemiol Biomarkers Prev, 2018, 27(2):174-182.
［8］邓梅君, 刘俊, 李贵玲. 克唑替尼对人卵巢癌细胞系SKOV3细胞增殖的影响［J］. 医药导报, 2017, 36(7):727-730.
［9］Coffman LG, Burgos-Ojeda D, Wu R, et al. New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination［J］.Transl Res，2016, 175:92-102.
［10］Pereria D,Assis J,Gomes M，et al.Improvement of a predictive model in ovarian cancer patiens submitted to platinum-based chemotherapy:implications of a GST activity profile［J］. Eur J Clin Pharmacol，2016，72(5):545-553.
［11］Estellés A, Charlton CA, Blau HM. The phosphoprotein protein PEA-15 inhibits Fas- but increases TNF-R1-mediated caspase-8 activity and apoptosis［J］. Dev Biology, 1999, 216(1):16-28.
［12］Condorelli G , Vigliotta G , Trencia A , et al. Protein kinase C (PKC)-alpha activation inhibits PKC-beta and mediates the action of PED/PEA-15 on glucose transport in the L6 skeletal muscle cells［J］. Diabetes, 2001, 50(6):1244-1252.
［13］Whitehurst AW, Robinson FL, Moore MS, et al. The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions［J］. J Biol Chem, 2004, 279(13):12840-12847.
［14］Bartholomeusz C, Rosen D, Wei C, et al. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival［J］.Cancer Res, 2008, 68(22):9302-9310.
［15］Exler RE , Guo X , Chan D , et al. Biomechanical insult switches pea-15 activity to uncouple its anti-apoptotic function and promote erk mediated tissue remodeling［J］. Exp Cell Res, 2016, 340(2):283-294.
［16］Weng Z , Gao H , Hu J , et al. Isoalantolactone induces autophagic cell death in SKOV3 human ovarian carcinoma cells via upregulation of PEA-15［J］. Oncol Rep, 2016,35(2):833-840.
［17］Formstecher E, Ramos JW, Fauquet M, et al. PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase［J］. Dev Cell, 2001, 1(2):239-250.
［18］Mohammed HN, Pickard MR, Mourtada-Maarabouni M. The protein phosphatase 4- PEA15 axis regulates the survival of breast cancer cells［J］. Cellular Signal, 2016, 28(9):1389-1400.
［19］庄良武, 林岚, 陈捷,等. TRAIL联合顺铂诱导卵巢癌耐药细胞株COC1/DDP凋亡机制的研究［J］. 中国医学创新, 2016, 13(29):17-21.
［20］Krueger J, Chou FL, Glading A, et al. Phosphorylation of phosphoprotein enriched in astrocytes (PEA-15) regulates extracellular signal-regulated kinase-dependent transcription and cell proliferation［J］. Mol Biol Cell, 2005, 16(8):3552-3561.
［21］Florian J，Sulzmaier J ,Mohana K, et al.PEA-15 potentiates H-Ras mediated epithelial cell transformation through Phospholipase D ［J］.Oncogene,2012,26(7): 3547-3560.
［22］Sulzmaier F, Opoku-Ansah J, Ramos JW. Phosphorylation is the switch that turns PEA-15 from tumor suppressor to tumor promoter［J］.Small GTPases,2012, 3(3):173-177.

[1]	石大伟, 郑晓永, 靳晓丹, 赵晓曼, 陈杰, 杜幸军. XPC基因多态性rs2228001对接受卡培他滨为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 391-399.
[2]	黄凯歌, 许勤华, 王伟. 血糖、血钙对急性重症胰腺炎患者预后影响的交互作用及预测效能研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1227-1234.
[3]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[4]	刘乐, 齐文博, 白玉萍, 刘乾, 尹振宇, 李晓梅, 俞阳, 陈昊. 胃癌PD-1/PD-L1免疫检查点抑制剂免疫治疗影响因素分析[J]. 中国临床药理学与治疗学, 2022, 27(1): 95-101.
[5]	田亚丽, 奉林, 赵万, 谷敏, 沈涵菁, 柴晓艳. BRCA1基因多态性与转移性食管鳞癌顺铂联合卡培他滨化疗敏感性及预后关系[J]. 中国临床药理学与治疗学, 2021, 26(10): 1118-1126.
[6]	许宏磊, 徐炳欣, 俎青, 赵艳, 高朋飞, 于洋. CYP2C19基因多态性对老年急性脑梗死患者应用氯吡格雷临床预后的影响[J]. 中国临床药理学与治疗学, 2020, 25(9): 1014-1020.
[7]	汪向海, 邢敏, 吕镗烽, 刘红兵, 宋勇. 敲降长链非编码RNA 00467表达对肺腺癌患者预后的影响及其机制[J]. 中国临床药理学与治疗学, 2020, 25(8): 841-849.
[8]	张德志, 刘猛, 朱少功, 刘桂举, 季节. XELOX方案对比卡培他滨单药方案在老年结直肠癌患者术后辅助化疗中的疗效及安全性探讨[J]. 中国临床药理学与治疗学, 2020, 25(8): 926-936.
[9]	李荣振，梅家转，夏云展，季节. 真实世界中R0切除术后结直肠癌患者接受卡培他滨为基础辅助化疗的预后影响因素及安全性探讨[J]. 中国临床药理学与治疗学, 2019, 24(6): 704-711.
[10]	白艳，郑晓永，杨雅阁，方立峰. 程序性死亡配体1基因遗传变异对术后结直肠癌患者接受5-FU为基础辅助化疗预后的影响[J]. 中国临床药理学与治疗学, 2019, 24(2): 180-187.
[11]	李文书，董淮富. 血清降钙素原在细菌性脑膜炎中的价值[J]. 中国临床药理学与治疗学, 2019, 24(11): 1315-1320.
[12]	李晓洁，张胜威，王华胜，王东，梅家转，邓业巍. VEGF-A基因多态性对接受氟尿嘧啶为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2018, 23(8): 900-904.
[13]	单艳，李志刚. TNFAIP3基因遗传变异对食管鳞癌患者预后的影响[J]. 中国临床药理学与治疗学, 2018, 23(7): 820-824.
[14]	陈冬，陆滢，裴仁治，娄引军，王敬瀚，叶佩佩，张丕胜，金洁. 小剂量高三尖杉酯碱联合全反式维甲酸及三氧化二砷治疗急性早幼粒细胞白血病的临床研究[J]. 中国临床药理学与治疗学, 2018, 23(5): 561-569.
[15]	吕文龙，陈秀英，洪金省，刘锋，张纬建. 基于CT测量的食管肿瘤体积对5-Fu联合顺铂同步放化疗疗效的预测价值[J]. 中国临床药理学与治疗学, 2018, 23(12): 1373-1379.

PEA-15 磷酸化状态与卵巢上皮性癌预后的相关分析

Correlation between phosphorylation of PEA-15-Ser104 site and prognosis of epithelial ovarian cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价